StockUK listing UK0EAPLSEEarnings Deterioration

Euroapi(0EAP) Stock Analysis

EUR --+0.00%
Reward45Moderate
Risk53Moderate
25%Data
Thin -41% profit margin · Revenue down 14% YoY
EUR —+0.00 (+0.00%) Previous close · LSE
Market cap —
Reward Ratingⓘ45 Moderate reward assessment · 25% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ53 Moderate risk assessment · 50% data coverage
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0EAP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Euroapi?

develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

AI Brief Pro

The brief on Euroapi

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Euroapi?

develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. The company is listed on the LSE in UK.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (45)
Company Information
SectorN/A
IndustryN/A
Beta1.013
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.